Loading…
Block, Report, and Suspend Suspicious Shipments Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
83pct
112d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (11)
Placed on the Union Calendar, Calendar No. 46.
Committee on the Judiciary discharged.
Committee on the Judiciary discharged.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-66, Part I.
Congress.gov source codes: 5000, H12200
Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.
Committee Consideration and Mark-up Session Held.
Committee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 28 - 0 .
Subcommittee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2024 · fourth_quarter · Health Issues
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES
2024 · fourth_quarter · Copyright/Patent/Trademark
Changes to Hatch-Waxman's 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Proposal related to drug shortages.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Pharmacy
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 9886/S. 5271 BUPE for Recovery Act and H.R. 5526 Seniors Access to Critical Medications Act.
Client expense: Not reported · Firm income: $20,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · fourth_quarter · Health Issues
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 9886/S.5271 BUPE for Recovery Act and H.R. 5526 Seniors' Access to Critical Medications Act.
Client expense: Not reported · Firm income: $20,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · fourth_quarter · Health Issues
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Client expense: $560,000 · Firm income: Not reported
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Markup By |
| March 23, 2023 |
| Judiciary Committee | House | Referred To | January 25, 2023 |
| Energy and Commerce Committee | House | Referred To | January 25, 2023 |
| Republican |
| AZ |
| Kim Schrier | Democratic | WA |
| Marcus J. Molinaro | Republican | NY |
| Susie Lee | Democratic | NV |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
Womens Health Protection Act Mental Health Workforce Shortages Federal policies affecting access to contingency management services for substance use disorders S. 4246 Advancing Menopause Care and Mid-Life Womens Health Act General Menopause health policy H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3752 Parity Enforcement Act of 2023 H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act H.R. 6284/S. 3260 Improving Measurements for Loneliness and Isolation Act of 2023 H.R. 6475 Health Disparity Zones Act of 2023 H.R.6928 CONNECT Act of 2024 H.R. 7153/S. 3679 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7301 Certified Community Behavioral Health Clinic Expansion Act of 2024 H.R. 8390 Mental Health and MAMA Act of 2024 H.R. 8503 Integrated Care for Dual Eligibles H.R. 9577 STOP Suicide Act H.R. 10073 Medicare Patient Access and Practice Stabilization Act of 2024 S.669/H.R. 8458 Increasing Mental Health Options Act of 2023 S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2733, PEER Support Act H.R. 7808, EARLY Minds Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act (PACE Act) S. 3393 SUPPORT for Patients and Communities Reauthorization Act S.3498 Promoting Effective and Empowering Recovery Services in Medicare Act of 2023 S. 3557 Public Health Impact of Opioid Drugs S. 3769, Alternative Pathways to Child Abuse Prevention Act S. 4312 United States Senate Commission on Mental Health Act of 2024 S. 4338 Pay PCPs Act of 2024 Reauthorization of the Older Americans Act Caregiving for older adults Title IV-B of the Social Security Act Mental Health Parity Final Rule Meeting with the Tri-Departments (DOL, HHS and Treasury) H.R 3312, S. 1602, Moms Matter Act S.4811, Prevention Services for Youth Act S.4812, Strengthening Supports for Youth Act H.R.9875, Child Safety and Well-Being Act Response to RFI regarding regulation of cannabis and hemp products Research regarding the safety and efficacy of psychedelic-assisted therapy Meeting with CMS on eligibility of postdoctoral training programs for Nursing/Allied Health Reimbursement Flexibility to prescribe certain controlled medications via telehealth for the treatment of mental health and substance use disorders Support of the proposed rule on georouting solutions for the 988 Suicide & Crisis Lifeline (988 Lifeline) Medicare coverage policies regarding mental health and substance use disorder services Sickle Cell Disease Comprehensive Care Act (H.R. 7432 / S. 5097)
Client expense: $350,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office
2024 · third_quarter · Health Issues
Womens Health Protection Act Mental Health Workforce Shortages Meeting with various administrative agencies on expanding access to mental health care in rural areas Forthcoming House bill on capital investments in rural mental health Federal policies affecting access to contingency management services for substance use disorders H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3752 Parity Enforcement Act of 2023 H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act H.R. 6284/S. 3260 Improving Measurements for Loneliness and Isolation Act of 2023 H.R. 6475 Health Disparity Zones Act of 2023 H.R.6928 CONNECT Act of 2024 H.R. 7301 Certified Community Behavioral Health Clinic Expansion Act of 2024 H.R. 8390 Mental Health and MAMA Act of 2024 H.R. 8503 Integrated Care for Dual Eligibles H.R. 9577 STOP Suicide Act S.669/H.R. 8458 Increasing Mental Health Options Act of 2023 S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2688 / H.R. 5116, the Behavioral Health IT Coordination Act S. 2733, PEER Support Act H.R. 7808, EARLY Minds Act H.R. 6407 / S. 3297, Medical Nutrition Therapy Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act (PACE Act) S. 3393 SUPPORT for Patients and Communities Reauthorization Act S.3498 Promoting Effective and Empowering Recovery Services in Medicare Act of 2023S. 3557 Public Health Impact of Opioid Drugs S. 3769, Alternative Pathways to Child Abuse Prevention Act S. 4312 United States Senate Commission on Mental Health Act of 2024 S. 4338 Pay PCPs Act of 2024 Dear Colleague letter to CMS re: coverage of digital therapeutics Reauthorization of the Older Americans Act Caregiving for older adults Title IV-B of the Social Security Act H.R. 3432/S. 3651, Telemental Health Care Access Act Mental Health Parity Final Rule Meeting with the Tri-Departments (DOL, HHS and Treasury) H.R 3312, S. 1602, Moms Matter Act S.4811, Prevention Services for Youth Act S.4812, Strengthening Supports for Youth Act H.R.9875, Child Safety and Well-Being Act Response to RFI re: 21st Century Cures 2.0 Response to RFI regarding regulation of cannabis and hemp products Research regarding the safety and efficacy of psychedelic-assisted therapy Flexibility to prescribe certain controlled medications via telehealth for the treatment of mental health and substance use disorders Support of the proposed rule on georouting solutions for the 988 Suicide & Crisis Lifeline (988 Lifeline) Medicare coverage policies regarding mental health and substance use disorder services
Client expense: $400,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Faith-Based & Community Initiatives, Office of Management & Budget (OMB), SENATE, Treasury, Dept of
2024 · third_quarter · Health Issues
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · third_quarter · Pharmacy
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act; H.R. 7513/S. 3679 Dr. Loma Breen Health Care Provider Protection Reauthorization Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · third_quarter · Health Issues
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Client expense: $640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Client expense: Not reported · Firm income: Not reported
2024 · second_quarter · Copyright/Patent/Trademark
Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages.
Client expense: Not reported · Firm income: Not reported
2024 · second_quarter · Health Issues
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act.
Client expense: Not reported · Firm income: $20,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · second_quarter · Pharmacy
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act.
Client expense: Not reported · Firm income: $20,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · second_quarter · Health Issues
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Client expense: $650,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Womens Health Protection Act Mental Health Workforce Shortages Meeting with various administrative agencies on expanding access to mental health care in rural areas Forthcoming House bill on capital investments in rural mental health Federal policies affecting access to contingency management services for substance use disorders H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2400 The Reentry Act H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3548 Pursuing Equity in Mental Health Act H.R. 3752 Parity Enforcement Act of 2023 H.R. 3759 Barriers to Suicide Act of 2023 H.R. 3850/S.3949 Pride in Mental Health Act H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act H.R. 6284/S. 3260 Improving Measurements for Loneliness and Isolation Act of 2023 H.R. 6475 Health Disparity Zones Act of 2023 H.R.6928 CONNECT Act of 2024 H.R. 7301 Certified Community Behavioral Health Clinic Expansion Act of 2024 H.R. 8390 Mental Health and MAMA Act of 2024 H.R. 8503 Integrated Care for Dual Eligibles S.669/H.R. 8458 Increasing Mental Health Options Act of 2023 S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S. 1426/H.R. 4541 Rise from Trauma Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2688 / H.R. 5116, the Behavioral Health IT Coordination Act S. 2733, PEER Support Act Response to Senator Bill Cassidy Request for Information re: patient data privacy Federal policies affecting the use of contingency management services for the treatment of stimulant use disorders H.R. 7808, EARLY Minds Act H.R. 6407 / S. 3297, Medical Nutrition Therapy Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act (PACE Act) S. 3393 SUPPORT for Patients and Communities Reauthorization Act S.3430 Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.3498 Promoting Effective and Empowering Recovery Services in Medicare Act of 2023S. 3557 Public Health Impact of Opioid Drugs S. 3769, Alternative Pathways to Child Abuse Prevention Act S. 4312 United States Senate Commission on Mental Health Act of 2024 S. 4338 Pay PCPs Act of 2024 Dear Colleague letter to CMS re: coverage of digital therapeutics Reauthorization of the Older Americans Act Elder Justice Act Title IV-B of the Social Security Act H.R. 7432, Sickle Cell Comprehensive Care Act H.R. 3432/S. 3651, Telemental Health Care Access Act Congressional briefing on telehealth and H.R. 3432 Congressional briefing on caregiving and mental health Congressional Briefing on A Population Health Approach to Youth Substance Use Disorder Prevention Congressional Briefing on Caucus on the Commission on the Social Status of Black Men and Boys Mental Health Parity Final Rule Meeting with the Tri-Departments (DOL, HHS and Treasury) H.R. 2412, Helping Kids Cope Act H.R 3312, S. 1602, Moms Matter Act
Client expense: $500,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Faith-Based & Community Initiatives, Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of
2024 · second_quarter · Health Issues
Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). S. 1067, Ensuring Timely Access to Generics Act. S. 1339, Pharmacy Benefit Manager Reform Act. S. 1114, Expanding Access to Low-Cost Generics Act of 2023. S. 1552, A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable. S. 1543, A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third-party administration services. Biosimilar Red Tape Elimination Act (S. 2305). Appeal of a decision regarding the CTPAT Program (DHS).
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
2024 · first_quarter · Health Issues
Strategic National Stockpile. Essential Medicines Strategic Stockpile Act (H.R.405). Ensuring essential medication supply for military and Department of Defense. Digital communication of prescribing information. Prescription Information Modernization Act (H.R.1503/S.2916). Drug Shortages. Block, Report and Suspend Suspicious Shipments Act (H.R.501). Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S.2510/H.R.6802). SUPPORT Act Reauthorization (S.2433/H.R.4531). FY2024 National Defense Authorization Act. FY2025 National Defense Authorization Act. House E&C Drug Shortages Discussion Draft. FY 2024 Continuing Resolution.
Client expense: $1,190,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · first_quarter · Health Issues
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · first_quarter · Pharmacy
Medication safety; pharmacy regulation and licensure, drug supply chain security and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/S 2433 SUPPORT for Patients and Communities Reauthorization Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · first_quarter · Health Issues
Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). S. 1067, Ensuring Timely Access to Generics Act. S. 1339, Pharmacy Benefit Manager Reform Act. S. 1114, Expanding Access to Low-Cost Generics Act of 2023. S. 1552, A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable. S. 1543, A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third-party administration services. Biosimilar Red Tape Elimination Act (S. 2305). Appeal of a decision regarding the CTPAT Program (DHS).
Client expense: $1,330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE
2024 · first_quarter · Health Issues
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Client expense: $1,580,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Health Issues
Womens Health Protection Act Mental Health Workforce Shortages Coding and reimbursement for digital therapeutics devices (DTx) and services furnished via DTx Meeting with various administrative agencies on expanding access to mental health care in rural areas Forthcoming House bill on capital investments in rural mental health Federal policies affecting access to contingency management services for substance use disorders H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2400 The Reentry Act H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3432/S. 3651 Telemental Health Care Access Act H.R. 3548 Pursuing Equity in Mental Health Act H.R. 3752 Parity Enforcement Act of 2023 H.R. 3759 Barriers to Suicide Act of 2023 H.R. 3850/S.3949 Pride in Mental Health Act H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4892, Medicaid Bump Act H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act H.R. 6284/S. 3260 Improving Measurements for Loneliness and Isolation Act of 2023 H.R. 6475 Health Disparity Zones Act of 2023 H.R.6928 CONNECT Act of 2024 S.669 Increasing Mental Health Options Act of 2023 S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S. 1426/H.R. 4541 Rise from Trauma Act S. 1736, Farmers First Act S. 2016 / H.R. 4189, CONNECT for Health Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2688 / H.R. 5116, the Behavioral Health IT Coordination Act S. 2733, PEER Support Act H.R. 4736, the Investing in Rural America Act Response to Senator Bill Cassidy Request for Information re: patient data privacy Federal policies affecting the use of contingency management services for the treatment of stimulant use disorders H.R. 7808, EARLY Minds Act H.R. 6524 / S. 1077, Home-Based Telemental Health Care Act H.R. 6407 / S. 3297, Medical Nutrition Therapy Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act (PACE Act) S. 3393 SUPPORT for Patients and Communities Reauthorization Act S.3430 Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.3498 Promoting Effective and Empowering Recovery Services in Medicare Act of 2023S. 3557 Public Health Impact of Opioid Drugs S. 3769, Alternative Pathways to Child Abuse Prevention Act H.R. 6487, No Fees for EFTs Act H.R. 3730/S. 198, Rural Health Clinic Burden Reduction Act H.R. 6407/S. 3297, Medical Nutrition Therapy Act Coalition letter to CMS opposing inclusion of HR 824 in funding package Meeting with CMS CIIO Office re: future rulemaking under the No Surprises Act Meeting with CMS and House/Senate offices re: coverage of digital therapeutics Reauthorization of the Older Americans Act Elder Justice Act Title IV-B of the Social Security Act H.R. 2762, the Tribal Family Fairness Act H.R. 3461, the Strengthening Tribal Families Act H.R. 2412, Helping Kids Cope Act H.R 3312, S. 1602, Moms Matter Act
Client expense: $400,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Faith-Based & Community Initiatives, Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of
2023 · fourth_quarter · Health Issues
Strategic National Stockpile. Essential Medicines Strategic Stockpile Act (H.R.405). Ensuring essential medication supply for military and Department of Defense. Digital communication of prescribing information. Prescription Information Modernization Act (H.R.1503/S.2916). Drug Shortages. Block, Report and Suspend Suspicious Shipments Act (H.R.501). Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S. 2510). SUPPORT Act Reauthorization (S.2433/H.R.4531). FY 2024 National Defense Authorization Act. House E&C Drug Shortages Discussion Draft. FY 2024 Continuing Resolution.
Client expense: $510,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Alcohol and Drug Abuse
H.R. 501, the Block, Report, and Suspend Suspicious Shipments Act; S. 2666, the E-Prescribing Parity for Controlled Substances Act Remote Prescribing of Controlled Substances
Client expense: $330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Health Issues
H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act
Client expense: $720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Health Issues
H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 895 Combating Organized Retail Crime Act H.R. 1613 Drug Price Transparency in Medicaid Act 2023 H.R. 1770 The Equitable Community Access to Pharmacist Services Act S. 113 Prescription Pricing for the People Act S. 127 Pharmacy Benefit Manager Transparency Act S. 140 Combating Organized Retail Crime Act
Client expense: $325,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · fourth_quarter · Pharmacy
Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/ S 2433 SUPPORT for Patients and Communities Reauthorization Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2023 · fourth_quarter · Health Issues
Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth; HR 4531/ S 2433 SUPPORT for Patients and Communities Reauthorization Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2023 · fourth_quarter · Health Issues
Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). S. 1067, Ensuring Timely Access to Generics Act. S. 1339, Pharmacy Benefit Manager Reform Act. S. 1114, Expanding Access to Low-Cost Generics Act of 2023. S. 1552, A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable. S. 1543, A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third-party administration services. Biosimilar Red Tape Elimination Act (S. 2305).
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Health Issues
Womens Health Protection Act Mental Health Workforce Shortages Coding and reimbursement for digital therapeutics devices (DTx) and services furnished via DTx Meeting with various administrative agencies on expanding access to mental health care in rural areas Forthcoming House bill on capital investments in rural mental health Federal policies affecting access to contingency management services for substance use disorders H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 773/S. 3165, Homelessness and Behavioral Health Care Coordination Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2400 The Reentry Act H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R.2577/S.1137,DHS Suicide Prevention and Resiliency for Law Enforcement Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3432 Telemental Health Care Access Act H.R. 3548 Pursuing Equity in Mental Health Act H.R. 3752 Parity Enforcement Act of 2023 H.R. 3759 Barriers to Suicide Act of 2023 H.R. 3850, Pride in Mental Health Act H.R.4310/S.2233, Youth Poisoning Protection Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4892, Medicaid Bump Act H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 H.R.4974, Local 988 Response Act H.R. 5866, Substance Use Disorder and Family Engagement (SAFE) in Recovery Act S.669 Increasing Mental Health Options Act of 2023S. S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819 COMPLETE Care Act S. 1426/H.R. 4541 Rise from Trauma Act S. 1736, Farmers First Act S. 2016 / H.R. 4189, CONNECT for Health Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804, The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2688 / H.R. 5116, the Behavioral Health IT Coordination Act S. 2733, PEER Support Act H.R. 4736, the Investing in Rural America Act Response to Cassidy Request for Information re: patient data privacy (9/28) Follow-up with various offices on APA Digital Therapeutics coding proposal Federal policies affecting the use of contingency management services for the treatment of stimulant use disorders Set aside of prevention and early intervention in the Community Mental Health Block Grant H.R. 6524 / S. 1077, Home-Based Telemental Health Care Act H.R. 6407 / S. 3297, Medical Nutrition Therapy Act S.3364, Kids Providing Resources for Optimal Outcomes Against Fatalities Act of 2024 (KID Proof Act) S.3085, Preventing Adverse Childhood Experiences Act( PACE Act)
Client expense: $330,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2023 · third_quarter · Health Issues
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: $530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
Advancing Emergency Preparedness through One Health Act. Strengthening Americas Strategic National Stockpile Act. Essential Medicines Strategic Stockpile Act. Ensuring essential medication supply for military and Department of Defense. National Defense Authorization Act. digital communication of prescribing information. Prescription Information Modernization Act. Implementation of Consolidated Appropriations Act. Drug Shortages. H.R. 501 - Block, Report and Suspend Suspicious Shipments Act. Pandemic and All Hazards Preparedness Reauthorization. Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S. 2510). SUPPORT Act Reauthorization. FY 2024 National Defense Authorization Act. Medical and Health Stockpile Accountability Act of 2023 (H.R.3577). Drug Origin Transparency Act of 2023 (H.R. 3810). E&C and Finance Request for Information (RFI) to Inform Policymaking on Drug Shortages. House E&C Drug Shortages Discussion Draft.
Client expense: $410,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Pharmacy
General issues related to opioid abuse and access to medication assisted treatment. H.R.501 - Block, Report, and Suspend Suspicious Shipments Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
General American Indian/Alaska Native healthcare Womens Health Protection Act Mental Health Workforce Shortages Coding and reimbursement for digital therapeutics devices (DTx) and services furnished via DTx Meeting with various administrative agencies on expanding access to mental health care in rural areas Forthcoming House bill on capital investments in rural mental health Federal policies affecting access to contingency management services for substance use disorders H. R. 498 / S.1493, 9-8-8 Lifeline Cybersecurity Responsibility Act H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 824, Telehealth Benefit Expansion for Workers Act H.R. 1359/S. 644 Modernizing Opioid Treatment Access Act H.R. 1423 911 Community Crisis Responders Act of 2023 H.R. 1502 Comprehensive Opioid Recovery Centers Reauthorization Act of 2023 H.R. 2400 The Reentry Act H.R. 2474 - The Strengthening Medicare for Patients and Providers Act H.R. 3074/S. 971 The Due Process Continuity of Care Act HR 3305 Black Maternal Health Momnibus Act H.R. 3375 STOP Fentanyl Overdoses Act H.R. 3432 Telemental Health Care Access Act H.R. 3752 Parity Enforcement Act of 2023 H.R. 3759 Barriers to Suicide Act of 2023 H.R. 3850, Pride in Mental Health Act H.R. 4531 / S. 2433, SUPPORT for Patients and Communities Reauthorization Act of 2023 H.R. 4851, 9-8-8 Implementation Act of 2023 H.R. 4892, Medicaid Bump Act H.R. 4884 /S. 2476 Mental Health for Latinos Act of 2023 S.669 Increasing Mental Health Options Act of 2023S. S. 923 Better Mental Health Care for Americans Act S. 1378/ H.R 5819COMPLETE Care Act S. 1426/H.R. 4541 Rise from Trauma Act S. 1736, Farmers First Act S. 2016 / H.R. 4189, CONNECT for Health Act S.2350, National Strategy for Social Connection Act Reintroduction of The Behavioral Health Coverage Transparency Act Reintroduction of The Parity Enforcement Act of 2023 H.R. 5804The Mental Health Infrastructure Improvement Act Reintroduction of The Comprehensive Addiction Resources Emergency Act Reintroduction of The Stop Online Suicide Assistance Forums Act S.2511, the ADAPT Act S. 2688 / H.R. 5116, the Behavioral Health IT Coordination Act S. 2733, PEER Support Act Sept. 19 USDA event on Farm Suicides H.R. 4736, the Investing in Rural America Act Response to Sen. Bill Cassidy (R-LA) Request for Information re: patient data privacy (9/28) Comment in response to Proposed Rules re: Short-Term Limited Duration Insurance (8/30) Follow-up with various offices on APA Digital Therapeutics coding proposal Federal policies affecting the use of contingency management services for the treatment of stimulant use disorders
Client expense: $280,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2023 · third_quarter · Health Issues
Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth.
Client expense: Not reported · Firm income: $40,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2023 · third_quarter · Pharmacy
Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth.
Client expense: Not reported · Firm income: $40,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2023 · third_quarter · Manufacturing
Drug Supply Chain Security Act (DSCSA); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Education on supply chain issues, raw material shortages, drug shortages, ports and transportation issues, Buy America, domestic manufacturing, medical device sterilization; Stop Drug Shortages Act; Supply chain issues and delays related to US border crossings.
Client expense: $220,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · third_quarter · Health Issues
Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). S. 1067, Ensuring Timely Access to Generics Act. S. 1339, Pharmacy Benefit Manager Reform Act. S. 1114, Expanding Access to Low-Cost Generics Act of 2023. S. 1552, A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable. S. 1543, A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third-party administration services.
Client expense: $300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Health Issues
H.R. 501 Block, Report, And Suspend Suspicious Shipments Act H.R. 895 Combating Organized Retail Crime Act H.R. 1613 Drug Price Transparency in Medicaid Act 2023 H.R. 1770 The Equitable Community Access to Pharmacist Services Act S. 113 Prescription Pricing for the People Act S. 127 Pharmacy Benefit Manager Transparency Act S. 140 Combating Organized Retail Crime Act
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2023 · third_quarter · Pharmacy
H.R. 501-Block, Report, And Suspend Suspicious Shipments Act. Legislative proposals to prevent and respond to drug shortages.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Alcohol and Drug Abuse
H.R. 501, the Block, Report, and Suspend Suspicious Shipments Act; S. 2666, the E-Prescribing Parity for Controlled Substances Act
Client expense: $360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Pharmacy
General issues related to opioid abuse and access to medication assisted treatment. H.R.501 - Block, Report, and Suspend Suspicious Shipments Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.
Client expense: $510,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Advancing Emergency Preparedness through One Health Act. Strengthening Americas Strategic National Stockpile Act. Essential Medicines Strategic Stockpile Act. Ensuring essential medication supply for military and Department of Defense. National Defense Authorization Act. digital communication of prescribing information. Prescription Information Modernization Act. Implementation of Consolidated Appropriations Act. Drug Shortages. H.R. 501 - Block, Report and Suspend Suspicious Shipments Act. Pandemic and All Hazards Preparedness Reauthorization. FDA Risk Evaluation and Mitigation Strategy (REMS) and Distribution of FDA-Approved Womens Health Medication. Drug Supply Chain Security Act Implementation. SUPPORT Act Reauthorization. FY 2024 National Defense Authorization Act. Medical and Health Stockpile Accountability Act of 2023 (H.R.3577). Drug Origin Transparency Act of 2023 (H.R. 3810). E&C and Finance Request for Information to Inform Policymaking on Drug Shortages
Client expense: $450,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Manufacturing
Pharmaceutical Supply Chain Risk Assessment Act of 2023 (S. 1961); Drug Supply Chain Security Act (DSCSA); Block, Report, and Suspend Suspicious Shipments Act (H.R. 501); Education on supply chain issues, raw material shortages, drug shortages, ports and transportation issues, Buy America, domestic manufacturing, medical device sterilization.
Client expense: $200,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2023 · second_quarter · Pharmacy
H.R. 501-Block, Report, And Suspend Suspicious Shipments Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic including ensuring MOUD access; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2023 · second_quarter · Pharmacy
Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2023 · second_quarter · Health Issues
Use of Section viii statements in pharmaceutical labeling. FDAs approval of over-the-counter naloxone nasal spray. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and reform efforts affecting pharmacy benefit managers, including Pharmacy Benefit Manager Transparency Act (S. 127), Prescription Pricing for the People Act (S. 113), and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613). Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S.142), Affordable Prescriptions for Patients Act (S.150). Block, Report, and Suspend Suspicious Shipments Act (H.R. 501). Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). S. 1067, Ensuring Timely Access to Generics Act. S. 1339, Pharmacy Benefit Manager Reform Act. S. 1114, Expanding Access to Low-Cost Generics Act of 2023. S. 1552, A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable. S. 1543, A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third-party administration services.
Client expense: $1,330,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE